Announcements Trials
Browse Landscape

Phase

Phase 1 101Phase 1/2 58Phase NA 36Phase 2 29Phase 3 7Phase EARLY_PHASE1 2Phase 2/3 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 24Breast 3Other 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 76Colorectal Neoplasms 55Carcinoma, Hepatocellular 51Stomach Neoplasms 34Colonic Neoplasms 26Breast Neoplasms 23Lung Neoplasms 15Rectal Neoplasms 12Ovarian Neoplasms 12Liver Neoplasms 12Sarcoma 11Gastrointestinal Neoplasms 11Neoplasms 10Esophageal Neoplasms 10Barrett Esophagus 9Melanoma 7Head and Neck Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 5Neoplasm Metastasis 4Colorectal Neoplasms, Hereditary Nonpolyposis 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Ductal Adenocarcinoma 3Osteosarcoma 3Esophageal Squamous Cell Carcinoma 3Disease 3Digestive System Neoplasms 3

Interventions

tislelizumab 1montelukast 1Taxes 1Tablets 1Paclitaxel 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Endometrial Neoplasms × Gastrointestinal × Clear all
NCT06887673 2025-03-20

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

University of South Florida

Phase EARLY_PHASE1 Not yet recruiting
56 enrolled
CNSGastrointestinalGynecologicSarcoma

Brain Neoplasms, Inflammation, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡